Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : EO2002,Ripasudil
Therapeutic Area : Ophthalmology
Study Phase : Phase I
Recipient : Asociación para Evitar la Ceguera en México
Deal Size : Inapplicable
Deal Type : Inapplicable
Study to Assess Safety and Tolerability of Multiple Doses of EO2002
Details : Undisclosed
Product Name : Undisclosed
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
December 05, 2022
Lead Product(s) : EO2002,Ripasudil
Therapeutic Area : Ophthalmology
Highest Development Status : Phase I
Recipient : Asociación para Evitar la Ceguera en México
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : EO2002,Inapplicable
Therapeutic Area : Ophthalmology
Study Phase : Phase I
Recipient : Asociación para Evitar la Ceguera en México
Deal Size : Inapplicable
Deal Type : Inapplicable
Study to Assess Safety and Tolerability of EO2002
Details : Undisclosed
Product Name : Undisclosed
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
October 19, 2022
Lead Product(s) : EO2002,Inapplicable
Therapeutic Area : Ophthalmology
Highest Development Status : Phase I
Recipient : Asociación para Evitar la Ceguera en México
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : EO2002,Inapplicable
Therapeutic Area : Ophthalmology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Study of Safety and Tolerability of EO2002 in the Treatment of Corneal Edema
Details : Undisclosed
Product Name : Undisclosed
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
May 20, 2021
Lead Product(s) : EO2002,Inapplicable
Therapeutic Area : Ophthalmology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : EO2002,Inapplicable
Therapeutic Area : Ophthalmology
Study Phase : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Emmecell Announces FDA Acceptance of IND Application for EO2002 in Corneal Edema
Details : The active IND enables Emmecell to initiate a Phase 1 clinical trial designed to assess the tolerability, safety, and efficacy of EO2002 in patients with corneal edema.
Product Name : Undisclosed
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
September 22, 2020
Lead Product(s) : EO2002,Inapplicable
Therapeutic Area : Ophthalmology
Highest Development Status : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : EO1404,Inapplicable
Therapeutic Area : Ophthalmology
Study Phase : Phase I
Recipient : Valeria Sanchez-Huerta
Deal Size : Inapplicable
Deal Type : Inapplicable
Phase 1 Study to Evaluate the Safety and Tolerability of EO1404 in the Treatment of Corneal Edema
Details : Undisclosed
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
December 10, 2019
Lead Product(s) : EO1404,Inapplicable
Therapeutic Area : Ophthalmology
Highest Development Status : Phase I
Recipient : Valeria Sanchez-Huerta
Deal Size : Inapplicable
Deal Type : Inapplicable